Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report

Marco Sposito, MD; Ilaria Mariangela Scaglione, MD; Serena Eccher, MD; Luca Pasqualin, MD; Alice Avancini, PhD; Chiara Colato, MD; Paolo Rosina, MD; Michele Simbolo, PhD; Anna Caliò, MD, PhD; Aldo Scarpa, MD; Michele Milella, MD; Sara Pilotto, MD, PhD; Lorenzo Belluomini, MD

JTO Clinical and Research Reports (Dec 2023)

Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report

Marco Sposito, MD,
Ilaria Mariangela Scaglione, MD,
Serena Eccher, MD,
Luca Pasqualin, MD,
Alice Avancini, PhD,
Chiara Colato, MD,
Paolo Rosina, MD,
Michele Simbolo, PhD,
Anna Caliò, MD, PhD,
Aldo Scarpa, MD,
Michele Milella, MD,
Sara Pilotto, MD, PhD,
Lorenzo Belluomini, MD

Affiliations

Marco Sposito, MD: Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy
Ilaria Mariangela Scaglione, MD: Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy
Serena Eccher, MD: Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy
Luca Pasqualin, MD: Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy
Alice Avancini, PhD: Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
Chiara Colato, MD: Section of Pathology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy
Paolo Rosina, MD: Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
Michele Simbolo, PhD: Section of Pathology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy
Anna Caliò, MD, PhD: Section of Pathology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy
Aldo Scarpa, MD: Section of Pathology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy
Michele Milella, MD: Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy
Sara Pilotto, MD, PhD: Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy; Corresponding author. Address for correspondence: Sara Pilotto, MD, PhD, Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, P. le L.A. Scuro 10, 37134 Verona, Italy.
Lorenzo Belluomini, MD: Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy

Journal volume & issue: Vol. 4, no. 12
p. 100597

Abstract

Read online

Background: Enteric-type adenocarcinoma of the lung (lung-ETAC) is a rare form of lung cancer with histologic similarities to colorectal cancer, with aggressive behavior and unfavorable prognosis. Case Presentation: An 81-year-old man presented with discolored skin lesions on the chest and abdomen. After comprehensive evaluation, including skin biopsy and molecular profiling, the patient was diagnosed with having lung-ETAC with a BRAF p.V600E mutation. Treatment with dabrafenib and trametinib initially resulted in positive results, with improvement in skin lesions and overall clinical condition. Nevertheless, approximately 6 months after, the disease had progression with new skin lesions reappearing. Conclusions: We reported a unique case of a patient with BRAF p.V600E-mutant lung-ETAC with metastatic skin lesions achieving complete cutaneous response after targeted treatment with dabrafenib and trametinib, highlighting the potential for targeted therapy in patients with lung-ETAC harboring a BRAF p.V600E mutation.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords